Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer
Latest Information Update: 12 Dec 2025
At a glance
- Drugs Dostarlimab (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms RW-NEDOS
Most Recent Events
- 12 Dec 2025 New trial record